HWM
KRYS icon

Hohimer Wealth Management’s Krystal Biotech KRYS Stock Holding History

Hohimer Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
1,038
+4
+0.4% +$1.2K 0.04% 248
2026
Q1 		$267K Sell
1,034
-180
-15% -$47.9K 0.03% 249
2025
Q4 		$299K Sell
1,214
-1
-0.1% -$210 0.04% 224
2025
Q3 		$214K Buy
+1,215
New +$182K 0.03% 297

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hohimer Wealth Management's KRYS Position: Q2 2026 in Review

Hohimer Wealth Management increased its Krystal Biotech (KRYS) stake by 0.39% in Q2 2026, buying an estimated $1.2K and bringing the position to 1,038 shares worth $386K. The position accounts for 0.04% of the portfolio, ranked #248.

Hohimer Wealth Management first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Hohimer Wealth Management held 1,038 shares of Krystal Biotech worth $386K as of Q2 2026.
  • Hohimer Wealth Management bought 4 Krystal Biotech shares in Q2 2026, an estimated $1.2K.
  • Krystal Biotech made up 0.04% of Hohimer Wealth Management's portfolio in Q2 2026, its #248 holding.
  • Hohimer Wealth Management first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.